Cyclosporine A and Chlorambucil in the Treatment of Idiopathic Focal Segmental Glomerulosclerosis

American Journal of Kidney Diseases

Volumn 43, Issue 1, 2004, Pages 10-18

  Heering, Peter ^a   Braun, Norbert ^b   Müllejans, Reinhard ^b   Ivens, Katrin ^b   Zäuner, Ingeborg ^b   Fünfstück, Reinhard ^b   Keller, Frieder ^b   Krämer, Bernhard K ^b   Schollmeyer, Peter ^b   Risler, Teut ^b   Grabensee, Bernd ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

Cyclosporine A (CsA); Focal segmental glomerulosclerosis (FSGS); Nephrotic syndrome

Indexed keywords

CHLORAMBUCIL; CREATININE; CYCLOSPORIN A; LIPID; STEROID; UREA;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GINGIVA HYPERTROPHY; HUMAN; HYPERTENSION; HYPERTRICHOSIS; IDIOPATHIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS; KIDNEY FAILURE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTIC SYNDROME; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN RESTRICTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; UREA NITROGEN BLOOD LEVEL;

EID: 9144258404     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.09.027     Document Type: Article

References (31)

1. Cameron JS, Turner DR, Ogg CS, Chantler C, Wiliams DG, on behalf of the German Collaborative Glomerulonephritis Study Group: The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 10:213-218, 1978
2. Korbet S, Swartz MM, Lewis EJ: Primary focal segmental glomerulosclerosis: Clinical course and response to therapy. Am J Kidney Dis 23:773-783, 1994
3. Grupe WE, Makker SP, Inglefinger JR: Chlorambucil treatment of frequently relapsing nephrotic syndrome. N Engl J Med 295:746-749, 1976
4. International Study of Kidney Disease in Children: Cyclophosphamide therapy in focal segmental glomerular sclerosis: A controlled clinical trial. Eur J Pediatr 140:149-153, 1983
5. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr: Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 10:590-593, 1996
6. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA: Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: A long-term follow-up. Clin Nephrol 43:84-88, 1995
7. Pei Y, Cattran D, Delmore T, Katz A, Lang A, Rance P: Evidence suggesting undertreatment in adults with idiopathic focal segmental glomerulosclerosis in adults. Am J Med 82:938-944, 1987
8. Braun N, Erley C, Benda N, et al: Therapy of membranous glomerulonephritis with a nephrotic syndrome. 5 years follow up of a prospective randomized multicenter study. J Am Soc Nephrol 6:413, 1995 (abstr)
9. DeSanto NG, Capodicasa G, Giordano C: Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin. Am J Nephrol 7:74-76, 1987
10. Brodehl J, Brandis M, Helmchen U: Cyclosporin A treatment in children with minimal nephrotic syndrome and focal segmental glomerulosclerosis. Klin Wochenschrift 66: 1126-1137, 1988
11. Collaborative Study Group of CsA in Nephrotic Syndrome: Safety and tolerability of CsA in idiopathic nephrotic syndrome. Clin Nephrol 135:48-60, 1991 (suppl 1)
12. Ambavalan S, Fauvel JP, Sibley RK, Myers BD: Mechanism of the antiproteinuric effect of CsA in membranous nephropathy. J Am Soc Nephrol 7:290-298, 1996
13. Heering P, Schneider A, Grabensee B, Plum J: Influence of cyclosporin on renal function in patients with glomerulonepritis. Deutsche Med Wochenschrift 126:1093-1098, 2001
14. Zietse R, Wenting GJ, Kramer P, Schalekamp MA, Weimar W: Effect of cyclosporin on glomerular barrier function in the nephrotic syndrome. Clin Science 82:641-650, 1992
15. Feutren G, Mihatsch MJ: Risk factors for CsA induced neuropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 326:1654-1660, 1992
16. Mihatsch M, Bach JF, Coovadia HM, et al: CsA associated nephropathy in patients with autoimmune disease. Klin Wochenschrift 66:43-47, 1988
17. Myers BD, Sibley R, Newton L, et al: The long term course of CsA associated chronic nephropathy. Kidney Int 33:590-600, 1988
18. Cattran DC, Appel GB, Hebert LA, et al: A randomized trial of cyclosporine in patients with steroid resistant focal segmental glomerulosclerosis. Kidney Int 56:2220-2226, 1999
19. Lee HY, Kim HS, Kang CM, Kim SG, Kim MJ: The efficacy of cyclosporin A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: A multicenter study in Korea. Clin Nephrol 43:375-381, 1995
20. Meyrier A, Condamin MC, Broneer D: Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: Minimal change disease and focal segmental glomerulosclerosis. Clin Nephrol 3:37-40, 1991
21. Meyrier A, Noel LH, Auriche P, Callard P: Long-term renal tolerance of cyclosporin A treatment in adult nephrotic syndrome. Kidney Int 45:1446-1456, 1994
22. Niaudet P, Habib R: CsA in the treatment of idiopathic nephrosis. J Am Soc Nephrol 5:1049-1056, 1994
23. Ingulli E, Tejani A: Severe hypercholesteremia inhibits Cyclosporin A efficacy in a dose dependant manner in children with nephrotic syndrome. J Am Soc Nephrol 3:254-259, 1992
24. Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A: Aggressive, long term CsA (CSA) therapy in refractory nephrotic syndrome (NS) blunts the progression of focal segmental glomerulosclerosis (FSGS) to end stage renal disease (ESRD). J Am Soc Nephrol 5:1820-1826, 1995
25. Ponticelli C, Rizzoni G, Edefonti A, et al: A randomized trial of CsA in steroid resistant idiopathic nephrotic syndrome. Kidney Int 43:1377-1384, 1993
26. Ponticelli C, Villa M, Banfi G, et al: Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 34:618-625, 1999
27. Green A, O'Meara Y, Sheehan Y, Carmody M, Doyle G, Donohoe J: The use of cyclosporin A in adult nephrotic syndrome: Nine cases and literature review. Ir J Med Sci 159:178-181, 1990
28. McCauley J, Shapiro R, Ellis D, Igdal H, Tzakis A, Starzl TE: Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 8:1286-1290, 1993
29. Haas M, Godfrin Y, Oberbauer R, et al: Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 13:2013-2016, 1998
30. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM: Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. Am J Kidney Dis 25:534-542, 1995
31. Banfi G, Moriggi M, Sabadini E, et al: The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 36:53-57, 1991